Stockreport

Mateon Therapeutics Team Publishes Three New Peer-Reviewed Oncology Articles Outlining the Clinical Impact Potential of Its First-In-Class Anti-TGF-Beta RNA Therapeutic OT101/Trabedersen

MATEON THERAPEUTICS  (MATN) 
Last mateon therapeutics earnings: 11/19 05:25 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.mateon.com
PDF AGOURA HILLS, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN, “Mateon”) dedi [Read more]